Sign In
Buy ALNY
$297.69
+5.53 (+1.89%)
At Close: Jun 09, 2026
Is the Options Market Predicting a Spike in Alnylam Pharmaceuticals Stock?
10:11am, Tuesday, 07'th Apr 2026
Investors need to pay close attention to ALNY stock based on the movements in the options market lately.
5 Biotechs That Big Pharma Could Snap Up as Oncology M&A Heats Up
07:05am, Wednesday, 01'st Apr 2026
Oncology M&A activity is accelerating as large pharmaceutical companies race to replenish pipelines facing patent cliffs and seek exposure to next-generation therapeutic platforms.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new clinical and real-world data from its cardiovascular (CV) po
Alnylam Pharmaceuticals, Inc. (ALNY) Discusses Progress and Strategy in Transforming ATTR Amyloidosis Care and Expanding TTR Franchise Transcript
Congress Asset Management Co. Boosts Position in Alnylam Pharmaceuticals, Inc. $ALNY
01:39pm, Tuesday, 24'th Mar 2026
Congress Asset Management Co. boosted its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) by 126.6% in the fourth quarter, according to its most recent 13F filing with the Securities a
Viz.ai Partners with Alnylam Pharmaceuticals to Advance Earlier Identification and Care Coordination in Cardiac Amyloidosis
09:00am, Tuesday, 24'th Mar 2026
SAN FRANCISCO--(BUSINESS WIRE)-- #ai--Viz.ai, the leader in AI-powered disease detection and care coordination, today announced a partnership with Alnylam Pharmaceuticals, the leading RNAi therapeutic
Alnylam Advances Future of ATTR-CM Care Through Strategic Collaboration with Viz.ai and Support for the American Heart Association
07:30am, Tuesday, 24'th Mar 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced a set of strategic efforts designed to accelerate earlier recogn
Can Alnylam's Pipeline Drugs Sustain Long-Term Growth Ahead?
11:36am, Thursday, 19'th Mar 2026
ALNY's strong drug sales and advancing pipeline, including late-stage candidates, are driving momentum and supporting its long-term growth outlook.
Bamco Inc. NY Acquires New Shares in Alnylam Pharmaceuticals, Inc. $ALNY
03:36am, Tuesday, 17'th Mar 2026
Bamco Inc. NY bought a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commissio
Pre-Market Stock Futures: The futures are trading higher as we start the new trading week. There is an old saying, "Fool me once, shame on you; fool me twice, shame on me." Well, the buy-the-dip crowd
Alnylam Pharmaceuticals, Inc. $ALNY Shares Bought by Anchor Investment Management LLC
03:26am, Monday, 16'th Mar 2026
Anchor Investment Management LLC grew its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) by 1,024.5% during the third quarter, according to the company in its most recent filing with the Sec
How Alnylam Stock Weathers Market Shocks
11:55am, Wednesday, 11'th Mar 2026
Investing in equities involves accepting volatility as the cost of long-term compounding. In 15 significant systemic shocks during which Alnylam Pharmaceuticals (ALNY) was traded, the stock experience
Alnylam to Webcast TTR Investor Webinar
08:00am, Tuesday, 10'th Mar 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming TTR Investor Webinar on the In
12,658 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Purchased by Fieldview Capital Management LLC
04:54am, Monday, 09'th Mar 2026
Fieldview Capital Management LLC acquired a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) during the undefined quarter, according to the company in its most recent disclosure with the S
Analysts Set Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Price Target at $477.96
02:54am, Monday, 09'th Mar 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY - Get Free Report) has received a consensus rating of "Moderate Buy" from the twenty-eight research firms that are covering the stock, Marketbeat.com report
